Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
M. McMahon, P. C. Ghazi, K. T. O'Toole, S. Srinivas Boggaram, M. T. Scherzer, M. R. Silvis, Y. Zhang, M. Bogdan, B. D. Smith, G. Lozano, D. L. Flynn, E. Snyder, C. G. Kinsey
This study shows that combining ULK1/2 inhibition with KRASG12C inhibitors reduces lung cancer growth in preclinical models.
bioRxiv · Feb 6, 2024Cancer Biology